Of those patients with HER2-negative breast cancer (N = 21), 20 of 21 (95%) received an anthracycline and taxane containing regimen (four with additional platinum agent, and another four with additional investigational agent on the I-SPY2 trial) and one (5%) received taxane (no anthracycline). The gene discussed is ERBB2; the disease is breast carcinoma.